Related Experiment Video
Updated: Dec 27, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Exploring Novel Molecular Targets for the Treatment of High-Grade Astrocytomas Using Peptide Therapeutics: An
Giulia Guidotti1, Liliana Brambilla1, Daniela Rossi1
1Istituti Clinici Scientifici Maugeri IRCCS, Laboratory for Research on Neurodegenerative Disorders, 27100 Pavia, Italy.
Abstract:
Diffuse astrocytomas are the most aggressive and lethal glial tumors of the central nervous system (CNS). Their high cellular heterogeneity and the presence of specific barriers, i.e., blood-brain barrier (BBB) and tumor barrier, make these cancers poorly responsive to all kinds of currently available therapies. Standard therapeutic approaches developed to prevent astrocytoma progression, such as chemotherapy and radiotherapy, do not improve the average survival of patients. However, the recent identification of key genetic alterations and molecular signatures specific for astrocytomas has allowed the advent of novel targeted therapies, potentially more efficient and characterized by fewer side effects. Among others, peptides have emerged as promising therapeutic agents, due to their numerous advantages when compared to standard chemotherapeutics. They can be employed as (i) pharmacologically active agents, which promote the reduction of tumor growth; or (ii) carriers, either to facilitate the translocation of drugs through brain, tumor, and cellular barriers, or to target tumor-specific receptors. Since several pathways are normally altered in malignant gliomas, better outcomes may result from combining multi-target strategies rather than targeting a single effector. In the last years, several preclinical studies with different types of peptides moved in this direction, providing promising results in murine models of disease and opening new perspectives for peptide applications in the treatment of high-grade brain tumors.
Insights
Peptides show promise for treating aggressive diffuse astrocytomas, offering new therapeutic strategies beyond traditional chemotherapy and radiotherapy for brain tumors.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Drug Discovery
Background:
- Diffuse astrocytomas are aggressive central nervous system (CNS) tumors with poor response to current therapies.
- High cellular heterogeneity and barriers like the blood-brain barrier (BBB) limit treatment efficacy.
- Standard chemotherapy and radiotherapy offer limited survival benefits for patients.
Purpose of the Study:
- To explore the potential of peptides as novel therapeutic agents for diffuse astrocytomas.
- To investigate peptides as active agents or drug carriers to overcome treatment barriers.
- To highlight the promise of multi-target peptide strategies in treating high-grade brain tumors.
Main Methods:
- Review of preclinical studies on peptide-based therapies for astrocytomas.
- Analysis of peptide advantages over conventional chemotherapeutics.
- Evaluation of peptides for drug delivery and targeting of tumor-specific receptors.
Main Results:
- Peptides demonstrate potential as pharmacologically active agents to reduce tumor growth.
- Peptides can function as carriers to facilitate drug translocation across brain and tumor barriers.
- Preclinical studies in murine models show promising results for peptide applications.
Conclusions:
- Peptides offer a promising avenue for novel targeted therapies against diffuse astrocytomas.
- Combining multi-target peptide strategies may improve outcomes for malignant gliomas.
- Peptide-based treatments present new perspectives for high-grade brain tumor management.
More Related Videos
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
07:25Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment
Published on: March 1, 2024
